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In the last decade, widespread use of E-cigarettes (EC) has occurred all over the world.
Whereas, a large amount of evidence on harm to children from conventional cigarette
exposure is available, data on health effects in this population throughout different
vulnerability windows are still a matter of concern. Exposure to EC during pregnancy may
compromise placental function, resulting in fetal structural abnormalities. Specifically, this
may cause physio-pathologic changes in the developing lung, which in turn may impair
respiratory health later in life. Furthermore, there is evidence that using EC can cause both
short- and long-term respiratory problems in the pediatric population and there is great
concern for future young people with nicotine addiction. The low parental perception of
the risks connected to EC exposure for children increases their susceptibility to harmful
effects from passive vaping. This minireview aims to summarize the current evidence
focusing on: (i) prenatal effects of EC passive exposure; (ii) post-natal respiratory effects
of EC exposure in youth; (iii) parental attitudes toward EC use and perception of children’s
health risks connected to EC exposure; and (iv) addressing gaps in our current evidence.
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INTRODUCTION
In the last decade, widespread use of E-cigarettes (EC) has occurred all over the world. EC are
electronic nicotine delivery systems (ENDS) composed of a battery-powered heating element that
aerosolizes a liquid solution comprising nicotine, propylene glycol (PG), and vegetable glycerin
(VG) as the main components. PG, VG, glycerol, and a variety of flavors (1) are the principal
components of vaping fluids. The heterogeneity of vaping fluid composition results in a large
variety of nicotine concentrations in liquids in di!erent brands and in the choicesmade by users (2).
After the initial models similar to tobacco cigarettes in size and shape, EC manufacturers have
developed various devices with refilling reservoirs and di!erent heating power, which allow the user
to mix e-liquids and choose the temperature of the vapor (3). However, the possibility of making up
e-liquids using variable concentrations of nicotine, other non-nicotinic components, and di!erent
flavors, associated with the absence of standardization for EC content by manufacturers, results in
inconsistent quality control processes (4).
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The use of flavors may have made EC more popular, especially
among pregnant women and adolescents (5). The attraction of
flavored products for pregnant women is likely due to alterations
in taste, cravings, nausea and high sensitivity to bitter tastes
which commonly occur during pregnancy. Moreover, flavorings
increase the appeal to youths who increasingly have started
smoking EC, serving as a gateway to cigarette smoking (5). In
addition, the fact that EC functioning is not based on combustion
and virtually does not produce a side-stream aerosol has led to
their widespread use in homes, cars, and other indoor settings
(6). Indeed, parents living in socio-economically disadvantaged
circumstances especially tend to consider EC as potentially
helpful to protect their children from passive smoke exposure in
the home (7).
To date, a large amount of evidence on harm to children
from conventional cigarette exposure is available (8), whilst
data on health e!ects in this population throughout di!erent
vulnerability windows remain a matter of concern. There is
growing evidence that exposure of pregnant women to EC may
impair placental function and may result in fetal structural
abnormalities. Furthermore, it appears that using EC can cause
both short- and long-term respiratory problems in the pediatric
population and there are fears that a future generation of youth
may be addicted to nicotine (Figure 1).
This minireview aims to summarize the current evidence
focusing on: (i) prenatal e!ects of EC passive exposure; (ii) post-
natal respiratory e!ects of EC exposure in youth; (iii) parental
attitudes toward EC use and perception of children’s health
risks connected to EC exposure; and (iv) addressing gaps in our
current evidence.
PRENATAL EFFECTS OF EC PASSIVE
EXPOSURE
The majority of negative e!ects of EC exposure in prenatal life
have been studied using in vitro and animal models, with limited
data obtained from studies conducted in humans. Emerging
evidence suggests that prenatal EC exposure may determine
placental compromise and consequent dangerous e!ects for the
fetus. Nicotine is known to be responsible for most of the e!ects,
but vaping aerosol contains many harmful chemicals other than
nicotine. Nicotine has a para-sympathomimetic stimulant e!ect.
Its ability to cross the placental barrier is responsible for the high
concentration in fetal serum and amniotic fluid (9).
The risks of smoking EC during pregnancy are still largely
unknown. However, evidence suggests that even nicotine-free
EC aerosols may cause harm to the fetus. The HTR8/SVneo
cells derived from transfected cells of human chorionic villi have
been used to study the function of placental cells exposed to
flavorless EC without nicotine, showing a significant reduction
in trophoblast impairment and angiogenesis functions, which
Abbreviations: AOR, adjusted odd ratio; DLCO, di!usion capacity of carbon
monoxide; EC, E-Cigarettes; ENDS, electronic nicotine delivery system; EVALI,
EC vaping associated lung injury; GLY, glycerol; RR, relative risk; PG,
propylene glycol; SGA, small-for-gestational-age; SHS, second-hand smoking; VG,
vegetable glycerin.
are vital for placental circulation (10). These results suggest that
placental cells may be vulnerable to exposure to EC aerosols,
even in the absence of nicotine, but these findings require
further studies.
A negative e!ect of EC has been demonstrated in cardiac
di!erentiation of human embryonic stem cells in vitro (11).
Moreover, when gravidmice were exposed to e-vapors containing
nicotine, there was an increase in pro-inflammatory cytokines,
namely TNF-a, in the lungs of their o!spring, whereas IL-1b was
suppressed. This occurred both with nicotine-free e-vapors and
nicotine-containing ones; therefore, these e!ects are probably
not explained by nicotine but rather by by-products (12).
Indeed, e-vapors also contains toxins along with heavy metals
and carcinogenic nitrosamines. Moreover, compounds used for
flavoring can themselves be toxic or break down into compounds
which may cause toxicity, inflammation, and oxidative stress
in the pregnant woman and can built up in the fetus, with
consequences for intrauterine development. Murine models
have also demonstrated that maternal e-vapor exposure during
pregnancy can a!ect respiratory and neurological functions (13).
With regard to neurodevelopmental consequences of maternal
EC use, adverse behavioral outcomes have been observed in mice
adult o!spring. Even without nicotine, being exposed daily to
PG/VG all through the gestation periodmay disrupt learning and
memory performance and cause a rise in neuro-inflammation
(14). Previously, Nguyen et al. identified changes in the behavior
of the o!spring of mice exposed to EC vapor with and without
nicotine during pregnancy: mice showed a higher rate of short-
termmemory deficits, learning disabilities, and increased anxious
behavior, were more hyperactive and tended to explore the
environment in risky ways compared to non-exposed ones. In
addition, global DNA methylation was increased and it was
found that 13 key genes were identified to be significantly altered
in the brains of EC exposed o!spring mice compared to the
non-exposed ones (15). A risk of renal impairment, including
increased kidney markers of oxidative stress, renal inflammation,
and fibrosis along with reduction of kidney volumes and function
in the adult o!spring was associated with EC use in pregnancy,
and these e!ects were found to be independent of the presence of
nicotine in the aerosols (16).
Harmful e!ects due to EC exposure in pregnancy have also
been reported in humans. Cardenas et al. evaluated tobacco use
in a cohort of 248 pregnant women, finding that those who
used ENDS had significantly lower gestational age-specific birth
weights than ones that did not smoke. The relative risk (RR) of
small-for-gestational-age (SGA) newborns was five times higher
than for women that did not smoke at all (17). Clemens et al.
compared birth outcomes among 76 women who smoked both
EC and tobacco cigarettes and women who did not smoke at
all. They found that women who smoked both EC and tobacco
cigarettes had a 7.8 times higher risk for SGA newborns than
women that did not smoke at all (18). However, it should be
pointed out that in both the studies population was limited in
size; therefore, findingsmay not be generalizable. Moreover, most
of the enrolled women were dual users and analyses were not
adjusted for cotinine level in order to evaluate di!erential impact
of tobacco exposure vs. nicotine exposure on SGA. Consequently,
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FIGURE 1 | Effects related to EC exposure throughout different vulnerability windows.
the reported results should be interpreted with caution, given
that tobacco smoking is associated with SGA. In a more recent
survey on 1,594 pregnant women, most of them dual users,
estimated adjusted RR for SGA for dual users was slightly higher
with respect to cigarette-only smokers [1.8 (95% CI: 1.0, 3.4)
vs. 1.7 (95% CI: 1.1, 2.7)]. These RR estimates increased after
correcting for tobacco use misclassification. Dual users who
continued using ENDS but stopped smoking cigarettes had an
increased risk for SGA compared with non-tobacco users [3.2
(95% CI: 1.5, 6.6)] (19). Furthermore, data from 55,251 pregnant
women who participated in the Phase 8 survey of the Pregnancy
Risk Assessment Monitoring System between 2016 and 2018
confirmed that EC use cannot be considered a safer alternative
to conventional cigarette (CC) smoking during pregnancy, as EC
and CC users showed not significantly di!erent risk on SGA, low
birth weight and preterm birth (20). Lastly, with regard to the
e!ects of the chemical components of e-vapors, they have not
been thoroughly defined in human studies so far, but it has been
suggested that certain populations, including pregnant women,
could process PG di!erently to the general population, being
prone to PG accumulation (21).
Overall, both in animal and human studies evidence of
harmful e!ects related to EC exposure during prenatal life has
been provided.
POST-NATAL RESPIRATORY EFFECTS OF
EC EXPOSURE IN CHILDHOOD
To date, little information is available regarding the e!ect of EC
exposure on children’s respiratory health. The available data on
pulmonary symptoms are inconsistent. A survey conducted on
3,488 schoolchildren aged 6–17 years in Switzerland investigated
the association between active smoking of CC, EC and shishas
and current respiratory symptoms, and found that dyspnea and
wheeze were more widespread among frequent smokers, i.e.,
those who smoked at least once/week (30 and 12%, respectively),
and occasional smokers (22 and 13%) than in never smokers
[19 and 8%, p < 0.05; (22)]. Similarly, a survey conducted on
44,662 Chinese students (mean age 14.6 years), reported that EC
use was significantly associated with respiratory symptoms, e.g.,
cough or phlegm for 3 consecutive months in the past 12 months
[adjusted OR (AOR), 1.28; 95% CI, 1.06–1.56)] (23). Likewise,
in a recent study on 2,086 adolescents aged 16–18 years who
took part in the Southern California Children’s Health Study,
self-reported wheeze in the last 12 months was associated with
current (OR [95% CI] = 1.86 [1.28–2.71]) but not past use of
EC. In the same study, chronic bronchitis symptoms during the
previous year were associated with both past (OR, 1.85; 95% CI,
1.37–2.49) and present use of EC (OR [95% CI] = 2.02 [1.42–
2.88]). The risk of bronchitis symptoms was directly proportional
to the number of days of EC use in the past month (OR [95%
CI] = 1.66 [1.02–2.68] for 1–2 days and OR [95% CI] = 2.52
[1.56–4.08] for >3 days), compared with non-EC users (p for
trend = 0.001) (24). More recently, in a cohort study of 7,049
adolescents, the association of EC use alone with wheezing in
the past 12 months proved not to be significant (25). Overall,
it should be pointed out that data from the aforementioned
studies are self-reported and may be subjected to recall bias.
Moreover, symptoms may have been interpreted in an inaccurate
way, especially by young children. Therefore, higher standards

























TABLE 1 | Respiratory effects of EC exposure in childhood.
References Country Study type Study population Aim and study
procedures
Results Comments
EC EXPOSURE AND RESPIRATORY SYMPTOMS
Mozun et al. (22) Switzerland School-based cross-sectional
study conducted in 2013–2016
3,488 children aged 6–17
years
Investigating the association
between active smoking of
conventional cigarettes, EC
and shishas and current
respiratory symptoms by
validated questionnaire
Dyspnea and wheeze were more frequent
among frequent smokers, i.e., those who
smoked at least once/week (30 and 12%,
respectively), and occasional smokers (22 and
13%) than in never smokers (19 and 8%,
p < 0.05)
Smoking EC and any other product, even
when occasional, was associated with
respiratory symptoms
Wang et al. (23) China Cross-sectional school-based
study conducted between 2012
and 2013
44,662 students (mean age
14.6 years)
Investigating the association
between active smoking of
EC and current respiratory
symptoms by questionnaire
EC use was significantly associated with
respiratory symptoms, e.g., cough or phlegm,
for 3 consecutive months in the last 12 months
(AOR, 1.28; 95% CI, 1.06–1.56)









associations of EC use with
chronic bronchitis
symptoms and wheeze by
questionnaire
Self-reported wheeze in the last 12 months
was associated with current (OR [95%
CI] = 1.86 [1.28–2.71]) but not with past use of
EC. Chronic bronchitis symptoms during the
previous year were associated with both past
(OR, 1.85; 95% CI, 1.37–2.49) and current use
of EC (OR [95% CI] = 2.02 [1.42–2.88]). The
risk of bronchitis symptoms increased with the
number of days of EC use in the last month
(OR [95% CI] = 1.66 [1.02–2.68] for 1–2 days)
and (OR [95% CI] = 2.52 [1.56–4.08] for >3
days), compared with EC never-users (p for
trend = 0.001)
Adolescent EC users had increased rates
of chronic bronchitis symptoms
Tackett et al. (25) U.S. Cohort study conducted




between EC use and
self-reported wheezing by
questionnaire
There was no significant association between
EC use alone and wheezing in the past 12
months was not significant (AOR for EC use in
the past year, 1.37 [95% CI, 0.91–2.05]; in the
past 30 days, 1.35 [95% CI, 0.63–2.88]; in the
past 7 days, 0.74 [95% CI, 0.28–1.97];
p = 0.33)
EC use alone was not associated with
increased risk of wheezing
EC EXPOSURE AND ASTHMA
Kim et al. (26) South Korea Cross-sectional web-based






passive, and EC smoking
with asthma
Significant associations between both active
and passive smoking with asthma (respectively:
AOR [95% CI] of smoking !20
days/month = 1.57 [1.38–1.77], p < 0.001;
AOR [95% CI] of smoking !5
days/week = 1.40 [1.28–1.53], p < 0.001).
Asthma prevalence was significantly higher in
the EC group (AOR [95% CI] = 1.13
[1.01–1.26], p = 0.027)
There was no significant association
between EC smoking in the last month
and was not significantly associated with
lifetime asthma after adjusting for active
and passive smoking, which were thus
considered to have a bigger role in



































































TABLE 1 | Continued
References Country Study type Study population Aim and study
procedures
Results Comments
Cho and Paik (27) South Korea Cross-sectional web-based
survey conducted in 2014
35,904 high school students
(mean age 16.4 years)
Investigating the association
between EC use and
asthma
EC users had an increased association with
asthma diagnosis (AOR [95% CI] = 2.74
[1.30–5.78], p < 0.01) than EC never-users.
Current EC users were more at risk for severe
asthma compared to “never EC” users (AOR
[95% CI] = 15.42 [5.11–46.57], p < 0.001)








between EC use and
asthma by means of a
questionnaire
There was a significant association between
current EC use and current asthma (AOR [95%
CI] = 1.48 [1.26–1.74]) and marginally
associated with any asthma ever (AOR [95%
CI] = 1.22 [1.07–1.40])
EC use is an independent risk factor for
current asthma
Han et al. (29) U.S. Cross-sectional surveys




between EC use and
asthma by questionnaire
Use of an e-vapor product was associated with
asthma especially when coupled with
marijuana, and even more when also combined
with cigarette smoking (AOR [95% CI] = 1.74
[1.44–2.10], p < 0.01). When adjusting for
frequent cigarette smoking and marijuana use,
there was a significant association between
frequent use of an e-vapor product (!10
days/month) and asthma (AOR [95%
CI] = 1.31 [1.11–1.54], p < 0.01)
E-vapor product use has additional
harmful effects on asthma when combined
with marijuana and cigarette smoking









between EC use and
asthma attacks by
questionnaire
The prevalence of ever and past-30-day use of
EC among those who reported asthma was
10.4 and 5.3%, respectively, which was
significantly higher than in those without
asthma (ever use = 7.2% and last 30-day
use = 2.5%; p < 0.01). Among students with
asthma, past-30-day use of EC was positively
associated with reporting an asthma attack in
the past 12 months (AOR [95% CI] = 1.78
[1.20–2.64])
EC use may have adverse health effects
among youth, especially those with
asthma
Bayly et al. (31) U.S. Cross-sectional survey
conducted in 2016
11,830 students with
asthma (age range: 11–17
years)
Investigating the association
between EC use and
asthma exacerbations by
means of questionnaire
Secondhand ENDS aerosol exposure was
associated with higher risk of asthma attacks in
the last 12 months (AOR [95% CI] = 1.27
[1.11–1.47])
Secondhand exposure to ENDS aerosols
may be related to asthma symptoms in
youth
EC EXPOSURE AND EVALI
Reddy et al. (32) U.S. Single-center retrospective case
series
6 adolescents (median age:
17 years)
To characterize EVALI in
critically ill adolescents
Broad spectrum of clinical presentation, testing
and imaging
There is increasing concern that patients



































































TABLE 1 | Continued
References Country Study type Study population Aim and study
procedures
Results Comments
Kaslow et al. (34) U.S. Single-center prospective case
series
7 adolescents (age range:
15–17 years)
To characterize EVALI in
adolescents
Broad spectrum of clinical presentation,
testing, and imaging
ENDS use can cause respiratory damage
in the pediatric population in both the
short and the long term
Carroll et al. (36) U.S. Single-center prospective case
series






Impairment of pulmonary function tests Serial testing of pulmonary function could
be useful in determining whether patients
achieve full resolution of symptoms or
whether there will be evidence of
irreversible pulmonary impairment
Rao et al. (37) U.S. Retrospective chart review 13 adolescents (mean age:






The use of corticosteroids resulted in
improvement in spirometry and DLCO; a 6-min
walking test was useful for identifying residual
lung disease in patients who had been taken
off oxygen due to clinical improvement with
glucocorticoid treatment
Lung function deficits due to EVALI appear
to be reversible with Steroids. The lone
patient who required veno-venous
extracorporeal membrane oxygenation
(VV-ECMO), and tracheostomy was
discharged with a home ventilator and
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p < 0.01). Interestingly, among students with asthma, use of
EC in the past 30 days was positively associated with an asthma
attack in the past 12 months (AOR [95% CI] = 1.78 [1.20–
2.64]) (30). Similarly, the 2016 Florida Youth Tobacco survey
showed that among students with a self-reported diagnosis of
asthma (n = 11,830), secondhand ENDS aerosol exposure was
associated with higher risk of asthma attacks in the past 12
months (AOR [95% CI] = 1.27 [1.11–1.47]) (31). It should be
acknowledged that both these studies did not provide details
about the variable “asthma attack/exacerbation” and this should
be considered when interpreting the reported findings.
In the last few years EC use has been associated with an
emergent condition known as “EC vaping associated lung injury”
(EVALI). A retrospective case series of six patients with a
median age of 17 years with confirmed or probable EVALI and
admitted to pediatric intensive care described the implications
of vaping on respiratory morbidity among adolescents, raising
the concern that patients with EVALI may have lasting lung
impairment (32). Indeed, it has been previously demonstrated
that a history of respiratory illness and/or a respiratory diagnosis
in childhood identified a group of cigarette smokers particularly
vulnerable to the harmful e!ects of smoking (33). Such e!ect
has not been reported so far with regard to EC use in youth.
In the study by Reddy et al., half of the patients had a pre-
existing diagnosis of asthma, two were positive for Rhinovirus
infection, and four had mental health comorbidities. In addition,
all patients reported both nicotine and THC use. Though the
clinical and radiological findings were similar to those described
in confirmed cases of adult EVALI, the study cohort was too
small to draw firm conclusions about an association with EC
use. Moreover, pulmonary function tests at discharge were
compromised only in one patient with pre-existing diagnosis
of asthma. Therefore, due to such limitations, these results
cannot be generalized and should be prudently evaluated.
Indeed, further investigation is required to clarify to what extent
EC use contributes to severe acute lung injury in patients
smoking multiple agents and whether asthmatics could be more
susceptible to potential harmful e!ects of EC use (32). Overall,
though the evidence is limited, it suggests that use of ENDS can
cause both short-term respiratory morbidity (i.e., cough, chest
pain, shortness of breath) and long-term abnormal spirometry
(most commonly obstructive pattern) in the pediatric population
(34). According to a very recent systematic review, pediatric
EVALI has been found in patients as young as 13 years of
age and often included respiratory symptoms. Typical findings
were the presence of ground-glass opacities on computed-
tomography and leukocytosis. Treatment mainly involved the
use of corticosteroids, antibiotics, and ventilatory support, and
extracorporeal membrane oxygenation, both when respiratory
failure occurred; outcomes ranged from complete or near
complete recovery of lung function to death (35). With regard to
lung function, in 15 adolescents hospitalized with EVALI, Carroll
et al. found that, before discharge, just over half of patients
had abnormal spirometry values with a restrictive pattern being
twice as frequent as obstruction. Sixty percent of those who
underwent di!usion studies showed decreased capacity to di!use
carbon monoxide (DLCO). About 4.5 weeks after discharge in
the majority of patients’ spirometry continued to be abnormal
(most frequently an obstructive pattern) (36). In addition, in
13 hospitalized adolescents with EVALI, Rao et al. showed
that corticosteroids produced an improvement in spirometry
and DLCO (37). Detection of toxicants in bronchoalveolar
lavage (BAL) fluid from patients with EVALI can provide direct
information on exposure within the lung. Recently, data from
Blount et al. linking the o!ending agent in EC showed that
Vitamin E acetate was associated with EVALI in a convenience
sample of 51 patients including adolescents aged 16 years. The
findings of the concentrations of vitamin E acetate in BAL fluid
from EVALI patients and the absence of vitamin E acetate in BAL
from healthy controls, and also the absence of other toxicants in
nearly all BAL fluid samples from EVALI patients suggest that
Vitamin E acetate may play a role in EVALI. Further studies
are requested to support a cause-e!ect relationship between
exposure to vitamin E acetate and the lung injury observed in
patients with EVALI (38). Similarly, a recent study on adults
found vitamin E acetate in all BAL specimens of a convenience
sample of 29 EVALI patients; however, more studies are needed,
since it is possible that more than one compound in EC could
contribute to lung injury, and evidence is still not robust to rule
out contribution of other toxicants to EVALI (39). Another study
linked o!ending agent in EC to EVALI, in contrast to other types
of smoking. In particular, Navon et al. reported that among adults
reporting use of THC-containing EC or vaping products, EVALI
patients had higher risk of reporting exclusive and frequent use
of THC-containing products which were mainly obtained from
informal sources. This reinforces current recommendations not
to use EC or vaping products containing THC, especially when
acquired from informal sources such as o! the street, from a
dealer, or from a friend (40).
Overall, the available evidence suggests that both active and
passive EC smoking put children’s and adolescents’ respiratory
health at risk (Table 1). This is a real concern mainly for those
who start smoking EC early in life. Moreover, the long-term
impact of EC smoking on respiratory symptoms and pulmonary
function needs to be further elucidated, especially in patients with
EC-associated lung injury.
BIOLOGICAL EVIDENCE OF HARMFUL
EFFECT OF EC ON THE AIRWAYS
Despite the lack of standard in vitro/ex-vivo and in vivo models,
data from available studies support the harmful e!ect of EC
on airway biology. In Table 2 the most recent evidence has
been summarized.
Di!erential e!ects in airway epithelial cells from non-smokers
and smokers were observed in a recent study comparing mucin
response to EC generated aerosols from PG and glycerol
(GLY). In details, the aerosol from the GLY exposure increased
MUC5AC levels in human nasal epithelial cells (hNECs) from
non-smokers. In addition, the PG:GLY with freebase nicotine
exposure increased MUC5AC andMUC5B levels in hNECs from
non-smokers (41). Of note, e-vapor exposure resulted harmful
as tobacco smoking in inducing morphologic di!erences in
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TABLE 2 | Biological evidence of EC on the airways.
References Aim Study procedures Results Comments
EC BIOLOGICAL EFFECTS IN VITRO/EX-VIVO
Escobar et al. (41) To compare mucin response to
EC generated aerosols from
propylene glycol (PG) and
glycerol (GLY) in airway cells from






cells (hNEC) from NS
and S exposed to
aerosols from PG, GLY,




The aerosol from the GLY exposure
increased MUC5AC levels in hNECs from
NS, and induced pro-inflammatory
responses in hNECs from S. The PG:GLY
with freebase nicotine exposure increased
MUC5AC and MUC5B levels in hNECs
from NS.
EC generated aerosols from the
humectants, mostly GLY, and type of
nicotine caused differential effects in
airway epithelial cells from NS and S.
Carson et al. (42) To characterize mucus
hypersecretion and accelerated
ciliary beat frequency (CBF)
subsequent to a single exposure
to tobacco smoke (TS) or EC









exposed to TS or EV.
Both TS and EV exposures resulted in
similar acute patterns of decline of CBF
and induced morphologic differences in
secretory function.
Similar pattern of epithelial response
to acute TS or EV exposure.
Woodall et al. (43) To investigate whether exposure
to PG or PG mixed with
vegetable glycerin (VG) (PG/VG)
would reduce glucose uptake in
human airway epithelial cells.
Exposure of H441 or
human bronchiolar
epithelial cells (HBECs)
to PG and PG/VG.
Inhibited glucose uptake and
mitochondrial ATP synthesis in H441 and
HBECs exposed to PG and PG/VG.
Reduced transepithelial electrical
resistance, and compromised glucose
transport function in PG/VG exposed cells.
Short-term exposure to PG/VG,
decreases glucose transport in airway
cells.
Herr et al. (44) To compare the acute effects of
traditional cigarettes (TCIGs) and
EC exposure on host defense,
inflammation, and cellular
activation of cell lines and
primary differentiated human
airway epithelial cells (pHBE).









In vitro: significant negative effects of
TCIGs on host defense and barrier
integrity in Calu-3 cells in comparison with
EC-exposed cells. Significant increased
IL-8 secretion from Calu-3 cells in
EC-exposed cells, similar to the amount
found after TCIG-exposure.
Ex-vivo: moderate increase of IL-8
secretion from Calu-3 cells in EC-exposed
cells as compared to TCIGs exposed cells.
Overall less effect of EC on epithelial
cells in comparison with TCIG
Ween et al. (45) To assess the effect of EC
constituents, 3 E-liquid apple
flavors, nicotine, VG, and PG, on
bronchial epithelial cell viability,
apoptosis, and cytokine
secretion and macrophage
phagocytosis of apoptotic airway
cells and phagocytic recognition
molecules.
In vitro: exposure of
THP-1 and 16HBE cell




pHBE cells to 3 E-liquid
apple flavors, nicotine,
VG, and PG.
In vitro: EC causes decreased
macrophage efferocytosis.
Ex-vivo: EC vapor increases pHBE cells
necrosis and apoptosis. Reduced
secretion of Tumor Necrosis Factor
(TNF)-!, Interleukin (IL)-6, Interferon
gamma-induced Protein (IP)-10,
Macrophage Inflammatory Protein
(MIP)-1! and MIP-1" was observed for all
flavor variants.
EC can cause bronchial epithelial
apoptosis and macrophage
efferocytosis dysfunction, and alter
bronchial epithelial cell cytokine
secretion pathways in a
flavor-dependent manner.
Ween et al. (46) To investigate the flavoring profile
of 10 different flavored E-liquids.














In vitro: flavor dependent
necrosis/apoptosis in 16HBE cells and
THP-1 differentiated macrophages
phagocytosis.
Banana and Chocolate reduced surface
expression of phagocytic target
recognition receptors on AM.
Ex-vivo: banana and chocolate increased
IL-8 secretion by NHBE.
The flavoring profile of E-liquids
increases bronchial epithelial cell
apoptosis, causes alveolar
macrophage phagocytic dysfunction,
and alters airway cytokines.
(Continued)
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TABLE 2 | Continued
References Aim Study procedures Results Comments








Significant cytotoxicity, with the “Mint”
flavor being the most cytotoxic. Significant
elevations in intracellular Ca2+,
upregulation of IL-6 and early apoptotic
marker Annexin V in “Mint” flavor exposed
cells.
JUUL e-liquid exposure results in a
loss of airway epithelial cell viability,
induces pro- inflammatory responses
and apoptosis
Rowell et al. (48) To characterize the effects of
e-liquids on cellular Ca2+
homeostasis.
In vitro: exposure of
Calu-3 and HEK-293T




(pHBE) to EC liquids.
In vitro: Acute e-liquid addition elicits
cytosolic Ca2+ responses in Calu-3 cells.
Banana pudding (BP): acutely elevates
cytosolic Ca2+ in Calu-3 and HEK-293T
cell lines; causes endoplasmic reticulum
(ER) Ca2+ release and store-operated
Ca2+ entry (SOCE) (notably, up to 24
h-exposure depletes ER Ca2+ stores and
inhibited SOCE) and protein kinase C
phosphorylation in Calu-3 cells.
Ex-vivo: BP acutely elevates cytosolic
Ca2+ in pHBE cell lines.
E-liquids may alter Ca2+ homeostasis
by short- and long-term mechanisms.
EC BIOLOGICAL EFFECTS IN VIVO







and EC users (vapers).
Epithelial cells from biopsy samples
revealed "300 proteins differentially
expressed in smoker and vaper airways,
with 113 proteins uniquely altered in
vapers.
Chronic vaping exerts marked
biological effects on the lung.
Staudt et al. (50) To assess whether acute
exposure to EC aerosols
modified the biology of the small








obtain SAE and AM, at
baseline and 1 week
later, after the inhalation
of EC (n = 7
randomized to EC with
nicotine and n = 3 to
EC without nicotine).
Altered transcriptomes of SAE and AM for
all subjects and elevated plasma EMP
levels following inhalation of EC with
nicotine.
Inhalation of EC aerosols dysregulates
human lung homeostasis in healthy
naïve individuals.
secretory function and eliciting acute decline of ciliary beat
frequency in airway epithelial cultures of non-smokers (42). In
line with these findings, short-term exposure to PG/VG was
found to decrease glucose transport in human airway epithelial
cells, suggesting that these EC constituents may alter defensive
properties of the respiratory epithelium (43). Conversely, Herr
et al., when comparing EC-vapor and traditional cigarettes
exposure, reported an overall less acute e!ect of EC on airway-
epithelial cell biology, although data in vitro did not allow
definitive conclusions about EC long-term safety (44).
The comprehensive harmful e!ect of EC constituents,
including E-liquid flavors, nicotine, VG and PG, has been
also investigated by Ween et al., showing increased bronchial
epithelial apoptosis and macrophage e!erocytosis dysfunction
in bronchial epithelial cells. Interestingly, the authors found
that EC can alter bronchial epithelial cell cytokine secretion
pathways in a flavor-dependent manner (45). In a more recent
study, the flavoring profile of E-liquids has been found to
cause bronchial epithelial cell apoptosis, alveolar macrophage
phagocytic dysfunction, and to alter airway cytokines, pointing
out the issue of regulating flavored E-liquids and the need ofmore
rigorous studies providing clear data on the health impacts of
flavored ECs (46). With particular regard to E-liquids mediated
e!ects, two recent studies reported inappropriate activation Ca2+
signaling pathways which in turn can have a detrimental impact
on cell function and survival resulting in a loss of airway epithelial
cell viability, and also in inducing pro-inflammatory responses
and apoptosis (47, 48).
In vivomodels confirmed that vaping exerts marked biological
e!ects on the lung, as demonstrated by proteomic investigation
that opened new research questions to be further explored about
the health impact of EC exposure (49). Inhalation of EC aerosols
has been found to dysregulate lung homeostasis even in healthy
naïve individuals (50). Overall, the available evidence suggests
that EC cannot be considered less dangerous than cigarette
smoking and that more studies are required to determine which
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components of EC aerosol and patterns of use contribute to the
damage to airway biology.
PARENTAL ATTITUDES TOWARD EC USE
AND PERCEPTION OF CHILDREN’S
HEALTH RISKS CONNECTED TO EC
EXPOSURE
The rapid growth in EC use is linked to advertising and
promotion marketing campaigns (51, 52) which have likely
contributed to increasing favorable perceptions, even among
pregnant women. Indeed, EC are thought to be a safer alternative
to conventional cigarettes and to help women quit smoking in
pregnancy (53), although it has not been demonstrated that using
them is e!ective with regard to the latter (54). Women may be
attracted to the flavorings due to alterations in taste that they
generally experience during pregnancy (55). Hence, flavors may
increase the appeal of EC in this population. In a study conducted
by Dobbs et al. on a sample of 219 pregnant women between
18 and 45 years, participants perceived that vaping during
pregnancy was significantly less risky than smoking conventional
cigarettes (56). A cross-sectional study on 176 pregnant smokers
(38% dual users), reported that, among dual users, 41% used
their EC daily. Overall, whereas the majority of participants
perceived EC use among women as acceptable, far fewer reported
this behavior as acceptable during pregnancy. Of note, 56%
perceived EC as harmful to women and 53% believed that EC risk
harming the fetus (57). Data from the Population Assessment of
Tobacco and Health (PATH) study showed that 4.9% of pregnant
respondents currently used EC, and most of them concurrently
used CC (58, 59). In a more recent study on 69,508 pregnant
women from 38 states in the U.S., the weighted prevalence of
EC use during the last 3 months of pregnancy was 1.1%. Among
women who smoked EC before being pregnant, 24.4% continued
to use EC during pregnancy. Among those who smoked EC
during pregnancy, 62.3% were dual users. Comparing smokers
with non-smokers before pregnancy the AOR was 6.7 (95% CI
4.4–10.3) for EC use during pregnancy (60).
A study on parents in socio-economically disadvantaged
circumstances reported that several of them who had tried,
currently used, or were planning to use EC considered these
products as potentially helpful to protect their children from
SHS exposure in the home (7). Notably, some di!erences in
smoke-free habits between parents who vape and parents who
smoke tobacco cigarettes have been noticed by Drehmer et al.
(61). Smoking parents are more likely to have stricter smoke-
free habits in cars and home than EC users or double smokers,
who more often allow others to vape when a child is present.
Moreover, limited knowledge about the harm of chemical
components of e-liquids often leads parents to refill their device
in the presence of their children without the necessary safety
precautions (61).
It should also be pointed out that parents actively shape
adolescent behavior with regard to EC use (62). Social factors
including peer or familial attitudes have a great influence on
susceptibility to becoming smokers or vapers. Youth with vaping
parents are significantly more likely to start vaping than others
(63). The determinants of this association may be emulation of
parental habits and low awareness of parental disapproval among
children and adolescents. Generally, a higher frequency of EC use
has been described among fathers, but the role of maternal use
in inducing adolescent vaping seems to be more influential (1).
Parents who smoke or vape, especially mothers, are more tolerant
toward their children vaping than non-smoking/vaper mothers.
A positive association between maternal and adolescence vaping
was shown by Sabbagh et al. (1). Patel et al. demonstrated that
a significant percentage of parents of middle- and high-school
children have poor knowledge about the commercial ENDS
variety and significantly underestimates their own children’s
vaping risk. The likelihood of their intervention in preventing or
stopping vaping-risk behaviors is dramatically low (64).
Overall, these findings suggest a low parental perception of
children’s health risks connected to EC exposure during both
prenatal and post-natal life.
A pediatric-o"ce based intervention may be a successful
strategy to advise parents about the risk connected to EC
exposure for their children’s health. A recently published policy
statement of the American Academy of Pediatrics recommends
that pediatricians screen for EC use and exposure in clinical
practice; provide counseling that homes, cars, and places where
children live should have comprehensive tobacco-free bans that
include EC; do not recommend EC as a tool for smoking
cessation (65). Based on the established relationship of trust with
parents, pediatricians could have a vital role in prevention of
EC use. Indeed, the pediatric visit may be an opportunity for
pediatricians to o!er smoking-cessation treatment to parents
and caregivers because parents generally see their children’s
pediatrician more often than their own healthcare provider.
Pediatricians can identify children exposed to passive smoke
and help parents and caregivers to quit, connecting them to
state quit-lines or to local cessation services, or prescribing them
with nicotine replacement therapy (NRT) (66). Even brief advice
can increase smoking cessation rates (67). The Clinical E!ort
Against Secondhand Smoke Exposure (CEASE) is a program
for addressing parental tobacco dependence that can be easily
implemented in the pediatrician’s o"ce. CEASE focuses on the
principles of ask, assist, and refer. In a 2-year randomized
clinical trial, implementing this program within pediatric o"ces
resulted in significantly higher rates of tobacco treatment
delivery, like prescription of NRT or quit line enrollment,
and a decline in parental smoking rates in comparison with
usual care (2.7 vs. 1.1%, respectively). This latter finding was
objectively confirmed by measurements of salivary cotinine in
parents, which demonstrated that smoking cessation can be
achieved, if pediatricians routinely screen parents for tobacco
use and o!er smoking cessation treatment (68). In spite of this
evidence, pediatricians reported poor self-e"cacy about smoking
cessation screening and counseling of parents and youth. Overall,
they were more confident about counseling youth than parents
(p < 0.01) and they identified pregnancy as the preferred time
window for their intervention.Moreover, though 93% considered
EC as dangerous as CC, 34% never counseled youth about the
hazards of vaping (69). This finding provides evidence that an
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adequate level of awareness is required among pediatricians to
improve communicative skills and strategies that could change
the parental approach to vaping.
Objective measurements of EC exposure in children might
help pediatricians to increase parental perception of children’s
health risks connected to EC exposure. Preliminary findings
of a study conducted on cigarette-exclusive, EC-exclusive, and
non-users and their children showed that caregivers using EC
perceived them as less harmful, and reported using them more
frequently at home and in the car, even when their children
were present, compared to cigarette users. Indeed, no significant
di!erence in levels of urinary cotinine was found between
children from the cigarette user group and those from the EC
user group, that appeared to be exposed to nicotine at levels
similar to children living with cigarette users (70). These findings
are in accordance with previous results obtained in adults (71)
and underline the need for targeted educational interventions for
caregivers around the potential harms of EC exposure in children.
Similar interventions should also involve adolescents, as a recent
study reported significantly greater toxicant exposure in EC users
compared with non-using peers. In particular, EC–only users had
up to 3 times urinary levels of 5 Volatile Organic Compounds
(VOCs). Since many of the VOCs were carcinogenic, and
they were present whether the product contained nicotine or
flavorings, EC users must be aware of the potential risk from
being exposed to carcinogenic compounds generated by these
products (72).
In summary, the involvement of pediatricians, nurses, and
other pediatric health care professionals is highly valuable. Given
the high prevalence of mental health problems in smokers,
EC users and drug users, pediatricians, and pediatric health
care professionals should carefully address all smoking and
vaping related health and mental health issues concurrently.
These issues often cannot be separated or addressed in isolation
without working on all the others in order to deliverer e!ective
patient care.
EC USE AND EXPOSURE DURING THE
COVID-19 PANDEMIC
With the implementation of social distancing due to Coronavirus
Disease 2019 (COVID-19) pandemic, isolation from the school
environment, loneliness, stress, and poor social support could
contribute to an increased EC use, particularly in adolescents
with pre-existing mental health conditions (73). In addition,
social media platforms for EC marketing, commonly frequented
by adolescents, have spread several unfounded health claims
about a protective role of EC against COVID-19 (74). Therefore,
it is not surprising that concerns have been recently raised
about the association of vaping, and its related e!ects, with
COVID-19, mainly in youth (75). Indeed, exposure to toxicant
compounds in EC suppresses immune function, increasing
susceptibility to infections (76). This explains why EC and dual
users show a higher risk of COVID-19 diagnosis in comparison
with non-users. Moreover, similar to smokers, it is plausible
that vapers could experience worse health outcomes with respect
to non-smokers. In particular, COVID-19 may cause acute
respiratory failure and ground glass opacities on chest imaging,
that may overlap with clinical manifestations and radiologic
findings of EVALI. As a further complication, the psychological
consequences of the COVID-19 pandemic may contribute to
increased cases of EVALI, given that EVALI patients reported
vaping more to cope with pandemic associated stressors and
anxiety (75–77). Moreover, EVALI and COVID-19 may co-
exist in some cases. Indeed, a significant number of EVALI
patients reported sharing the same device with friends and family
members, increasing their risk for SARS-CoV-2 infection (78).
Both EVALI and COVID-19 share some clinical features like
fever, cough, respiratory distress and non-specific gastrointestinal
symptoms. An elevation of inflammatory markers is observed
in both conditions, as well as radiological findings like bilateral
multifocal ground glass opacities, with or without consolidation
on chest CT imaging. However, EVALI remains an exclusion
diagnosis. Therefore, eliciting any vaping history in adolescents
with unexplained respiratory distress is crucial in making the
diagnosis, along with testing for SARS-coV-2 infection. Indeed,
treatment of EVALI di!ers from COVID-19, and early initiation
of steroids can be lifesaving and may reduce the length of
hospitalization (79).
Further studies addressing the relationship between EC use
and exposure and COVID-19 are required. Though youth are
generally considered at lower risk of developing COVID-19 than
older individuals, e!orts should be made in order to reduce
youth vaping and identify those susceptible to severe disease
outcomes (80). Longitudinal data are needed to explore whether
the detrimental interplay between EC use and COVID-19
might exacerbate lung injury in children a!ected by underlying
conditions, such as asthma. Further studies are also required to
investigate the long-term impact of SARS-CoV-2 infection on
respiratory health of children with or without underlying lung
diseases exposed to EC.
CONCLUSIONS
The widespread use of EC is an emerging threat to children’s
health. Studies have provided evidence about the health risks of
EC passive exposure, which are, in some respects, comparable
to those associated with passive tobacco exposure. However,
some research gaps should be addressed. First of all, the risks of
smoking EC during pregnancy need to be thoroughly elucidated;
in particular, further studies are needed to evaluate the placental
vulnerability to EC exposure. Secondly, prenatal e!ects of the
chemical components of e-vapors have not been thoroughly
defined in human studies so far. Research gaps also include lack of
generalizability and adjustment for confounders like tobacco use,
given that most of the subjects enrolled in the aforementioned
studies are dual users.
Little information is available regarding the e!ect of EC
exposure on children’s respiratory health. Available data are
mainly self-reported and may be subjected to recall bias.
Therefore, findings should be corroborated with medical records,
clinical assessment measures, or examination by physicians.
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Moreover, the long-term impact of EC smoking on respiratory
symptoms and pulmonary function needs to be further
elucidated, especially in patients with EC-associated lung injury.
Last but not least, more studies are required to determine which
components of EC aerosol and patterns of use contribute to the
damage to airway biology.
In the context of the current COVID-19 pandemic,
longitudinal data would be helpful to explore whether the
detrimental interplay between EC use and COVID-19 might
exacerbate lung injury in children a!ected by underlying
conditions, such as asthma. Further studies are also required to
investigate the long-term impact of SARS-CoV-2 infection on
respiratory health of children with or without underlying lung
diseases exposed to EC.
The low parental perception of the risks connected to
EC exposure for children throughout di!erent vulnerability
windows increases their susceptibility to harmful e!ects from
passive vaping, including prenatal damage and post-natal
respiratory e!ects, and increases the risk of vaping among
adolescents. Since the child’s home is the primary source of
exposure to tobacco smoke, addressing the issue of parental
perception of the harmful e!ects of EC exposure in children
is essential for promoting health, especially in more vulnerable
children such as those with respiratory chronic diseases
like asthma.
Pediatricians could play a crucial role in increasing
parental perception of children’s health risks connected to
EC use and exposure; at this purpose, they would benefit
from receiving ad-hoc training courses for promoting
smoking cessation in parents and adolescents (81). In this
context, further studies should explore the involvement of
pediatricians in smoking cessation programs for parents
and adolescents.
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